争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2025
印第安纳州起诉礼来公司涉嫌胰岛素价格操纵
提起诉讼
印第安纳州于12月31日在莱克县高等法院提起诉讼，指控礼来公司与药品福利管理机构合谋，通过秘密返利人为抬高胰岛素标价，部分胰岛素产品售价约300至700美元。礼来表示已采取行业领先措施降低胰岛素成本，包括将患者自付费用上限设为每月35美元并将标价下调70%。
品牌回应
否认 — Eli Lilly and Company
In a statement to WFYI, a company spokesperson said Lilly has taken “industry-leading” steps to lower insulin costs, including capping patient out-of-pocket costs at $35 per month and cutting list prices by 70%.
来源摘录
Indiana is suing Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical giant of inflating insulin prices through a coordinated pricing scheme involving secret rebates.
The lawsuit alleges Lilly conspired with pharmacy benefit managers to artificially inflate the sticker prices of insulin.
The lawsuit, filed Dec. 31 in Lake County Superior Court, builds on legal action Rokita took in March 2024 against other drug manufacturers and pharmacy benefit managers over insulin pricing.